亚洲地区心境稳定剂与抗抑郁药的联合临床应用：来自2004年和2013年亚洲抗抑郁药精神药物处方模式研究（REAP-AD）项目的报告
Clinical Use of Mood Stabilizers With Antidepressants in Asia: Report From the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Projects in 2004 and 2013.
作者信息
Rajaratnam Kamini, Xiang Yu-Tao, Tripathi Adarsh, Chiu Helen F K, Si Tian-Mei, Chee Kok-Yoon, Avasthi Ajit, Grover Sandeep, Chong Mian-Yoon, Kuga Hironori, Kanba Shigenobu, He Yan-Ling, Lee Min-Soo, Yang Shu-Yu, Udomratn Pichet, Kallivayalil Roy A, Tanra Andi J, Maramis Margarita M, Shen Winston W, Sartorius Norman, Kua Ee-Heok, Tan Chay-Hoon, Mahendran Rathi, Shinfuku Naotaka, Sum Min Yi, Baldessarini Ross J, Sim Kang
机构信息
From the *Department of General Psychiatry, Institute of Mental Health, Singapore; †Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China; ‡Department of Psychiatry, King George's Medical University, Chowk, Lucknow, India; §Department of Psychiatry, Chinese University of Hong Kong, Hong Kong; and ∥National Clinical Research Center for Mental Disorders & the Key Laboratory of Mental Health, Ministry of Health (Peking University), Peking University Institute of Mental Health (the Sixth Hospital), Beijing, China; ¶Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; #Department of Psychiatry, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India; **Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital-Kaohsiung Medical Center and School of Medicine, Chang Gung University, Taiwan; ††Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ‡‡Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China; §§Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea; ∥∥Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan; ¶¶Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; ##Department of Psychiatry, Pushpagiri Medical College, Thiruvalla, India; ***Department of Psychiatry, Hasanuddin University Faculty of Medicine, Makassar, Sulawesi Selatan; and †††Dr Soetomo Hospital - Faculty of Medicine, Airlangga University, Jawa Timur, Indonesia; ‡‡‡Departments of Psychiatry, TMU-Wan Fang Medical Center and School of Medicine, Taipei Medical University, Taiwan; §§§Association for the Improvement of Mental Health Programmes, Geneva, Switzerland; Departments of ∥∥∥Psychological Medicine and ¶¶¶Pharmacology, National University of Singapore, Singapore; ###International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan; ****Research Division, Institute of Mental Health, Singapore; ††††International Consortium for Mood & Psychotic Disorder Research, McLean Hospital, Belmont; and ‡‡‡‡Department of Psychiatry, Harvard Medical School, Boston, MA.
出版信息
J Clin Psychopharmacol. 2017 Apr;37(2):255-259. doi: 10.1097/JCP.0000000000000670.
OBJECTIVE
As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries.
METHODS
This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling.
RESULTS
Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose.
CONCLUSIONS
The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.
目的
由于大多数关于心境稳定剂（MS）与抗抑郁药（AD）联合治疗的报告都来自西方，我们调查了亚洲10个国家42个精神病护理机构中这种联合治疗的特征。
方法
这项横断面药物流行病学研究使用了2004年和2013年来自REAP-AD（亚洲抗抑郁药精神药物处方模式研究）的数据，采用标准双变量方法，随后进行多变量逻辑回归建模，以评估4164名精神病患者中与AD联合使用的MS的使用率和剂量以及相关因素。
结果
2004年至2013年间，MS + AD的使用率增加了104%（从5.5%增至11.2%），与双相情感障碍的诊断相关性远高于重度抑郁症或焦虑症，也与住院治疗>门诊治疗、精神科>普通内科项目以及年轻患者相关（所有P < 0.001），但与国家、性别或AD剂量无关。
结论
这些发现提供了亚洲目前MS与AD联合使用的大致情况，支持了近年来这种治疗有所增加且与双相情感障碍诊断、住院和精神科治疗以及年轻患者相关的预测。
Zotero 插件